NERVGEN PHARMA CORP.
NGEN evidence brief
What we can confirm
- Market Cap:
- $234.9M
What it means
What to watch
Prepared research question
What matters most for NGEN—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · NGEN
NervGen Pharma Corp. (NGEN) is a clinical-stage biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury (SCI) and other neurotraumatic and neurologic conditions, with its lead candidate NVG-291 advancing to Phase 3.
Key risk: Pre-revenue status
Market Cap
$234.9M
Cash Runway
—
Lead Asset
—
Next Catalyst
—
Tracking 2 clinical trials for NERVGEN PHARMA CORP..
NervGen Pharma Corp. (NGEN) is a clinical-stage biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury (SCI) and other neurotraumatic and neurologic conditions, with its lead candidate NVG-291 advancing to Phase 3.
- Lead drug NVG-291 is a first-in-class neuroreparative therapeutic for spinal cord injury [news · published 2026-04-07].
- Completed End-of-Phase 2 meeting with FDA, restoring Phase 3 registrational trial (RESTORE) for chronic tetraplegia [news · published 2026-04-07].
- Phase 3 trial (RESTORE) is a randomized, double-blind, placebo-controlled multicenter trial expected to start 2026-09-28 [catalyst].
- Completed a US$60.0 million public offering of securities in May 2026 [news · published 2026-05-22].
- Restated financial statements in September 2026 for non-cash accounting adjustments with no impact on cash or operations [news · published 2026-09-25].
What works
- NVG-291 demonstrated durable improvement in function, independence, and quality of life in chronic SCI in Phase 1b/2a CONNECT study [news · published 2026-02-11].
- Phase 3 registrational trial (RESTORE) is cleared by FDA, indicating regulatory alignment [news · published 2026-04-07].
- Company raised US$60.0 million in a public offering, providing capital for upcoming Phase 3 [news · published 2026-05-22].
What to weigh
- Company is pre-revenue and has not yet commercialized any product, relying on financing for operations [news · published 2026-05-22].
- Restatement of financial statements suggests prior accounting adjustments, though non-cash [news · published 2026-09-25].
- Phase 3 trial is expensive and carries execution risk; any delay could pressure cash runway [news · published 2026-03-17].
From the filings
Quoted directly from source documents.
NVG-291 is a first-in-class neuroreparative therapeutic for spinal cord injury.
“clinical-stage biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury (SCI) and other neurotraumatic and neurologic conditions”
News · April 7, 2026
Phase 3 trial (RESTORE) is a randomized, double-blind, placebo-controlled multicenter trial.
“A Trial Investigating the Efficacy and Safety of NVG-291 in Subjects With Chronic Spinal Cord Injury - A Randomized, Double-Blind, Placebo-Controlled Multicenter Phase 3 Trial (RESTORE)”
Catalysts · September 28, 2026
Company completed a US$60.0 million public offering in May 2026.
“NervGen Announces Pricing of US$60.0 Million Public Offering of Securities”
News · May 22, 2026
Restatement had no impact on cash or operations.
“Adjustments have no impact on cash and cash equivalents, cash runway, or business operations.”
News · September 25, 2026
Catalyst timeline
- 2026-09-28 · Phase 3 Start: RESTORE trial — A randomized, double-blind, placebo-controlled multicenter Phase 3 trial of NVG-291 in chronic spinal cord injury.
Risks & what to watch (3)›
Key risks
- Pre-revenue status — Company has no approved products and no revenue, relying entirely on financing [news · published 2026-05-22].
- Phase 3 execution risk — Phase 3 trial is expensive and may face delays; any setback could strain cash runway [news · published 2026-03-17].
- Accounting restatement — Restatement of financials for non-cash adjustments may raise governance concerns [news · published 2026-09-25].
What to watch
- Initiation and enrollment of Phase 3 RESTORE trial expected 2026-09-28 [catalyst].
- Cash runway and burn rate following the US$60M offering and restatement [news · published 2026-05-22].
- Any regulatory updates or FDA interactions regarding NVG-291 [news · published 2026-04-07].
Sources: Catalysts · News · Generated October 5, 2026 · How we verify sources →
Run NERVGEN PHARMA CORP. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available NERVGEN PHARMA CORP. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Regulatory
Financials
Frequently asked questions
What is the AI investment thesis for NERVGEN PHARMA CORP.?
NervGen Pharma Corp. (NGEN) is a clinical-stage biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury (SCI) and other neurotraumatic and neurologic conditions, with its lead candidate NVG-291 advancing to Phase 3.
Who is the CEO of NERVGEN PHARMA CORP.?
Dr. Adam H. Rogers M.D. is the chief executive officer of NERVGEN PHARMA CORP. (NGEN).
Where is NERVGEN PHARMA CORP. headquartered?
NERVGEN PHARMA CORP. (NGEN) is headquartered in Vancouver, BC, Canada.
What therapeutic areas does NERVGEN PHARMA CORP. focus on?
NERVGEN PHARMA CORP. develops therapies across Neurology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.